XML 59 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Emflaza asset acquisition - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Apr. 20, 2017
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]    
Issuance of common stock related to acquisition   $ 75,191
Intellectual Property    
Finite-Lived Intangible Assets [Line Items]    
Accumulated amortization   $ 15,400
Intellectual Property | Marathon Pharmaceuticals, LLC    
Finite-Lived Intangible Assets [Line Items]    
Cash consideration $ 75,000  
Issuance of common stock related to acquisition (in shares)   6,683,598
Issuance of common stock related to acquisition 75,190  
Acquisition costs $ 2,163  
Useful life 7 years  
Non-collaborative Arrangement Transactions [Member] | Marathon Pharmaceuticals, LLC    
Finite-Lived Intangible Assets [Line Items]    
Cash consideration $ 75,000  
Development and regulatory milestone payments which the entity may be obligated to pay $ 50,000